J Korean Med Assoc.  2014 Aug;57(8):704-709. 10.5124/jkma.2014.57.8.704.

Serum liver fibrosis test

• Sul AR

• KMID: 2194921
• DOI: http://doi.org/10.5124/jkma.2014.57.8.704

Abstract

The evaluation of fibrosis is crucial in the assessment of chronic liver disease. Liver biopsy has been a reference standard for assessing liver fibrosis. However, it has some drawbacks - invasiveness, risk of complications, and intra-observer/inter-observer variability. One of the promising tools for evaluating liver fibrosis is the Multivariate Index Assay, which combines the values of three biomarkers (hyaluronic acid, amino-terminal propeptide of type III procollagen, and tissue inhibitor of matrix metalloproteinase-1) from serum samples. A systematic review was conducted to determine whether the test would be a safe and effective method for assessing liver fibrosis. A total of 16 diagnostic studies on the serum liver fibrosis test have been reported. Based on the literature published until January 2013, this test is safe and can be used as an adjunct tool for detecting liver fibrosis in a wide range of chronic liver diseases.

Keyword

Liver cirrhosis; Hyaluronic acid; Amino-terminal propeptide of type III procollagen; Tissue inhibitor of metalloproteinase-1

MeSH Terms

Biomarkers
Biopsy
Collagen Type III
Fibrosis
Hyaluronic Acid
Liver
Liver Cirrhosis*
Liver Diseases
Tissue Inhibitor of Metalloproteinase-1
Collagen Type III
Hyaluronic Acid
Tissue Inhibitor of Metalloproteinase-1

Reference

1. Crespo G, Fernandez-Varo G, Marino Z, Casals G, Miquel R, Martinez SM, Gilabert R, Forns X, Jimenez W, Navasa M. ARFI, FibroScan, ELF, and their combinations in the assess-ment of liver fibrosis: a prospective study. J Hepatol. 2012; 57:281–287.

2. Kim BK, Kim HS, Park JY, Kim do Y, Ahn SH, Chon CY, Park YN, Han KH, Kim SU. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012; 7:e41964.

3. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007; 381:107–113.

4. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009; 136:160–167.

5. Crockett SD, Kaltenbach T, Keeffe EB. Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time? Clin Liver Dis. 2006; 10:513–534.

6. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008; 134:1670–1681.

7. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004; 127:1704–1713.

8. Stevenson M, Lloyd-Jones M, Morgan MY, Wong R. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technol Assess. 2012; 16:1–174.

9. National Institute for Health Research. National Horizon Scanning Centre. Enhanced Liver Fibrosis test (ELF) for evaluating liver fibrosis. Birmingham: National Horizon Scanning Centre;2008.

10. Kim DJ. Non-invasive diagnosis of liver fibrosis. Korean J Hepatol. 2005; 11:20–32.

11. Korean Ministry of Health and Welfare. Serum liver fibrosis test: new health technology assessment report. Seoul: Ministry of Health and Welfare;2013.

12. Guechot J, Trocme C, Renversez JC, Sturm N, Zarski JP. ANRS HC EP 23 Fibrostar Study Group. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med. 2012; 50:693–699.

13. Wahl K, Rosenberg W, Vaske B, Manns MP, Schulze-Osthoff K, Bahr MJ, Bantel H. Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS One. 2012; 7:e51906.

14. Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol. 2011; 9:150–155.

15. Martinez SM, Fernandez-Varo G, Gonzalez P, Sampson E, Bruguera M, Navasa M, Jimenez W, Sanchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011; 33:138–148.

16. Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011; 18:23–31.

17. Trepo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L, Cross R, Degre D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C, Sninsky J, Adler M, Wedemeyer H. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol. 2011; 55:38–44.

18. Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, Forns X, Jimenez W, Navasa M. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver trans-plantation. Gastroenterology. 2010; 138:147–158.

19. Cobbold JF, Crossey MM, Colman P, Goldin RD, Murphy PS, Patel N, Fitzpatrick J, Vennart W, Thomas HC, Cox IJ, Taylor-Robinson SD. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat. 2010; 17:537–545.

20. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010; 10:103.

21. Lee MH, Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Yang JM, Han KH, Cho SW. Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci. 2010; 55:3552–3560.

22. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A, Rosenberg W. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010; 59:1245–1251.

23. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008; 47:455–460.

24. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg WM. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008; 48:1549–1557.